Skip to main content

Table 2 Efficacy

From: Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer

 

arm A

arm B

 
 

(n = 25)

(n = 24)

p-value

CR

0

0

 

PR

9

4

 

SD

7

8

 

PD

8

5

 

NE

1

7

 

RR(%)

36.0

16.7

0.13

DCR(%)

64.0

50.0

0.32